Abstract:Objective: The axis of osteoprotegerin (OPG), the receptor activator for nuclear factor κB (RANK), and RANK ligand (RANKL) has been reported to be critical regulators of skeletal biology and calcification process. However, data was scarce on its involvement in intracranial arterial calcification. Design and method: Hypertensive patients with at least two cardiovascular risk factors were recruited from Shanghai Xinzhuang Community. Plasma OPG (Lifespan, Seattle, WA) and serum RANKL (Biomedica, Vienna, Austria) were measured with commercialized ELISA kits and log-transformed for analysis. Brain tomographic angiography (CTA) was performed with a GE FX/I helical CT scanner (General Electric, United States). The Hounsfield density was measured using a pixel lens on the CTA images. Calcification was defined as a focal high-density lesion of at least 120 Hounsfield units at the intracranial arteries. Pearson's correlation, single and multiple logistic regressions were applied for analysis. Results: The 831 patients (mean age, 65 years; 54% women) included 465 (56%) with intracranial arterial calcification. Mean clinic blood pressure was 137/72 mmHg and 736 (89%) patients were on anti-hypertensive treatment. Plasma OPG, but not serum RANKL, showed seasonal variation (P < 0.001), 15.6% higher (P < 0.001) in summer and 6.0% lower (P < 0.001) in autumn, relative to the mean level in the whole year. Plasma OPG was negatively associated with RANKL (r = −0.25; P < 0.001). The prevalence of intracranial arterial calcification increased with plasma OPG (49.1%, 56.8% and 61.9% in tertiles 1, 2, and 3, respectively; P = 0.003) and decreased with serum RANKL (61.6%, 54.8% and 49.2% in tertiles 1, 2, and 3, respectively; P = 0.005). In continuous analyses, RANKL, but not OPG (P = 0.57), remained significantly associated with intracranial arterial calcification after adjustment (OR [95%CL] associated with 1-SD increase: 0.63 [0.41, 0.99], P = 0.043). RANKL increased by 14.7% with total/HDL cholesterol ratio (P < 0.001), and decreased by 6.9% with neutrophils/lymphocyte ratio (P = 0.02). In pathway analysis, total/HDL cholesterol ratio had both a direct (P = 0.002) and RANKL-mediate indirect (P = 0.008) effect on intracranial arterial calcification. Conclusions: Circulating RANKL was associated with intracranial arterial calcification, highlighting that it might be a marker of intracranial arterial calcification. Further research is warranted to understand the precise mechanisms underpinning this association.

Association of bone-related protein with the presence of atherosclerosis and valvular calcification in CRF patients

Correlative study on the relationship between serum OPG and sRANK and coronary artery lesions in patients with coronary heart disease

Serum CX3CL1/fractalkine Concentrations Are Positively Associated with Disease Severity in Postmenopausal Osteoporotic Patients.

Cardiovascular risk markers associated with arterial calcification in patients with chronic kidney disease Stages 3 and 4

[BP.09.03] ASSOCIATION OF CIRCULATING OSTEOPROTEGERIN (OPG) AND RANKL WITH INTRACRANIAL ARTERIAL CALCIFICATION IN HYPERTENSIVE PATIENTS

Serum C-reactive protein is positively correlated with pathological changes of carotid artery and coronary calcification in elderly patients with coronary artery disease

A1762 Association of Circulating Osteoprotegerin (OPG) and RANKL with Intracranial Arterial Calcification in Hypertensive Patients

Associated Factors of Osteoporosis and Vascular Calcification in Patients Awaiting Kidney Transplantation.

A Study on the Relationship between Serum hs-CRP Level and the Risk of Cardiovascular Complications in Patients with Chronic Renal Disease

Biomarkers Associated with Vascular Calcification in Peritoneal Dialysis

[Expression and Significance of Inflammatory Factors and Bone Formation Mediators in Carotid Atherosclerotic Plaque].

The Relationship of Fetuin-A with Coronary Calcification, Carotid Atherosclerosis, and Mortality Risk in Non-Dialysis Chronic Kidney Disease

Undercarboxylated osteocalcin as a biomarker of subclinical atherosclerosis in non-dialysis patients with chronic kidney disease

THE ASSOCIATION OF SERUM INFLAMMATORY BIOMARKERS WITH CHRONIC KIDNEY DISEASE IN HYPERTENSIVE PATIENTS: PP.9.355

Association of serum 25-hydroxyvitamin D3, fibroblast growth factor-23, and C1q/tumor necrosis factor-related protein-3 with coronary artery calcification in nondialysis chronic kidney disease patients

Elevated Circulating Osteoprotegerin Levels in the Plasma of Hemodialyzed Patients With Severe Artery Calcification

C-reactive Protein As a Predictor for Cardiac Events in Chinese Elderly Patients with Coronary Heart Disease

Relationship between Serum Indoxyl Sulfate and Klotho Protein and Vascular Calcification in Patients with Chronic Kidney Disease Stages 3–5

Serum fetuin-A is associated with the components of MIAC(malnutrition, inflammation, atherosclerosis, calcification) syndrome in different stages of chronic kidney disease

Interrelations among Vascular Calcification, Bone Density, Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor Kb Ligand in Hemodialysis Patients

Correlation Between Serum C-reactive Protein Level and Carotid Atherosclerotic Plaque Calcification in Patients with Ischemic Stroke or Transient Ischemic Attack